Egfr-mutant non-small cell lung cancer accompanied by transient asymptomatic pulmonary opacities successfully treated with “stop-and-go” osimertinib

Keigo Kobayashi, Katsuhiko Naoki, Aoi Kuroda, Hiroyuki Yasuda, Ichiro Kawada, Kenzo Soejima, Tomoko Betsuyaku

研究成果: Article

抜粋

A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple che-motherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four weeks of osimertinib discontinuation, imaging revealed rapid lung cancer progression. Osimertinib was resumed. After 11 weeks, CT revealed decreased lung nodules with no exacerbation of interstitial lung disease. We describe a patient who experienced transient asymptomatic pulmonary opacities during treatment with osimertinib, which was successfully managed by a “stop-and-go” approach.

元の言語English
ページ(範囲)1007-1010
ページ数4
ジャーナルInternal Medicine
57
発行部数7
DOI
出版物ステータスPublished - 2018 1 1

    フィンガープリント

ASJC Scopus subject areas

  • Internal Medicine

これを引用